newsfilter
← Latest News
GlobeNewswire·

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Erasca, Inc. (ERAS) to Contact Law Firm

  • Moore Law, PLLC is investigating potential claims against officers and directors of Erasca, Inc. (NASDAQ: ERAS).
  • The firm alleges Erasca made false or misleading statements regarding its drug candidate ERAS-0015 without reasonable basis.
  • Allegations include improper comparisons of preclinical data to Revolution Medicines, Inc. (RevMed), creating risks of patent & trade secret violations.
  • On April 27, 2026, Erasca disclosed a Form 8-K revealing RevMed's legal counsel alleged ERAS-0015 infringes U.S. Patent No. 12,409,225 & involves trade secret misappropriation.
  • RevMed demanded Erasca cease deceptive comparative statements between ERAS-0015 & its drug RMC-6236.
  • Erasca stated it believes the assertions are without merit & intends to contest the allegations.
  • Erasca's stock price fell from $21.49 on April 24, 2026, to $19.15 on April 27, 2026, following the disclosure.
  • Shareholders may seek monetary damages, corporate governance reforms, reimbursement, & incentive awards at no cost under a contingency fee basis.
  • Interested shareholders should contact Fletcher Moore at fletcher@fmoorelaw.com.